Latest Update on Olomorasib Phase 1/2 Study Results at the 2024 ASCO Annual Meeting
Saturday, 1 June 2024, 09:12
Olomorasib Phase 1/2 Study Data Update
The presentation at the 2024 ASCO Annual Meeting offered insights and updates on the Phase 1/2 study of Olomorasib in KRAS G12C-mutant advanced solid tumors.
Promising Outcomes
- The updated data showcased positive results in the treatment of these specific types of tumors, indicating potential efficacy in targeted therapies.
The findings presented underscore the significance of ongoing research in developing effective treatments for patients with KRAS G12C-mutant tumors.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.